Payment overview · 2025
General Payments
$76.48
3 reported records · 3 companies
Healthcare provider profile · identity verified
Patrick Joseph Sammon, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · FOREST CITY, NC · NPI 1831407758
Verified facts
What the public records show
CMS Open Payments records show Patrick Joseph Sammon, PA received $76.48 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.62 | 38.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $23.89 | 31.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.97 | 30.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $76.48 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $22.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 864 | 216 |
| Amlodipine Besylate | Amlodipine Besylate | 584 | 147 |
| Lisinopril | Lisinopril | 478 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 441 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 377 | 97 |
| Gabapentin | Gabapentin | 349 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 87 |
| Clonazepam | Clonazepam | 306 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 289 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 277 | 70 |
| Alprazolam | Alprazolam | 276 | 52 |
| Jardiance | Empagliflozin | 271 | 46 |
| Omeprazole | Omeprazole | 270 | 79 |
| Metformin Hcl | Metformin Hcl | 249 | 61 |
| Famotidine | Famotidine | 236 | 60 |
| Lorazepam | Lorazepam | 234 | 55 |
| Losartan Potassium | Losartan Potassium | 230 | 67 |
| Trazodone Hcl | Trazodone Hcl | 229 | 51 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 221 | 58 |
| Sertraline Hcl | Sertraline Hcl | 221 | 50 |
| Montelukast Sodium | Montelukast Sodium | 199 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 51 |
| Potassium Chloride | Potassium Chloride | 191 | 40 |
| Meloxicam | Meloxicam | 182 | 55 |
| Furosemide | Furosemide | 181 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 176 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 55 |
| Carvedilol | Carvedilol | 166 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 35 |
| Eliquis | Apixaban | 161 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 161 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 159 | 29 |
| Metformin Hcl Er | Metformin Hcl | 158 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 47 |
| Buspirone Hcl | Buspirone Hcl | 153 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 40 |
| Ozempic | Semaglutide | 143 | 30 |
| Simvastatin | Simvastatin | 141 | 30 |
| Mounjaro | Tirzepatide | 134 | 25 |
| Tramadol Hcl | Tramadol Hcl | 134 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 129 | 24 |
| Alendronate Sodium | Alendronate Sodium | 127 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 123 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 24 |
| Valsartan | Valsartan | 118 | 27 |
| Diazepam | Diazepam | 115 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 33 |
| Allopurinol | Allopurinol | 111 | 28 |
| Prednisone | Prednisone | 99 | 67 |
| Ondansetron Odt | Ondansetron | 98 | 37 |
| Baclofen | Baclofen | 97 | 29 |
| Spironolactone | Spironolactone | 94 | 25 |
| Trulicity | Dulaglutide | 93 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 23 |
| Linzess | Linaclotide | 85 | 18 |
| Pregabalin | Pregabalin | 82 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 20 |
| Bupropion Xl | Bupropion Hcl | 78 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 19 |
| Azithromycin | Azithromycin | 72 | 45 |
| Warfarin Sodium | Warfarin Sodium | 71 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 70 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 23 |
| Glipizide Er | Glipizide | 68 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 17 |
| Ezetimibe | Ezetimibe | 66 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 15 |
| Mirtazapine | Mirtazapine | 63 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 62 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 51 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 19 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 35 |
| Donepezil Hcl | Donepezil Hcl | 54 | 16 |
| Glipizide | Glipizide | 54 | 15 |
| Telmisartan | Telmisartan | 52 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 52 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 17 |
| Farxiga | Dapagliflozin Propanediol | 51 | 14 |
| Glimepiride | Glimepiride | 51 | 14 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | suppressed |
| Bumetanide | Bumetanide | 47 | 15 |
| Celecoxib | Celecoxib | 46 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 11 |
| Ibuprofen | Ibuprofen | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 44 | suppressed |
| Fluconazole | Fluconazole | 44 | 32 |
| Olanzapine | Olanzapine | 44 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Movantik | Naloxegol Oxalate | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Belsomra | Suvorexant | 40 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 15 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Atenolol | Atenolol | 39 | 11 |
| Chlorthalidone | Chlorthalidone | 39 | 15 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Rybelsus | Semaglutide | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 28 |
| Estradiol | Estradiol | 37 | 11 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 15 |
| Synjardy | Empagliflozin/Metformin Hcl | 36 | suppressed |
| Clotrimazole | Clotrimazole | 35 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Nystatin | Nystatin | 32 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 17 |
| Methylprednisolone | Methylprednisolone | 29 | 29 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $76.48 · 3 records | ABBVIE INC. | CREON, LINZESS, Omnipod, WaveWriter Alpha Prime 16 | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error